Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the pharmaceutical
formulation comprises fulvestrant in solution, 17-23% weight of
a pharmaceutically-acceptable alcohol per volume of formulation, 12-18% weight of pharmaceutically-acceptable nanaqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45 mgml-1 of fulvestrant.
with dependent claims 20 to 22 to remain unchanged and claims